Bora Health Partners with Dr. Reddy’s Laboratories Ltd.
US FDA GRAS Approval for NTU101
2024
Ankascin products in the USA were honored as finalists in the 2024 NutraIngredients USA Awards.
“Launched the new Dr. B brand & established an agency agreement with Yen Yeh Research.
2023
Gained Taiwan’s health certification for anti-aging with our red yeast rice products.
Achieved 2023 NutraIngredients Awards recognition for Ankascin and other red yeast products in the U.S. and Asia.
Advanced red yeast rice standardization through a new chapter in the US Pharmacopeia.
Established a joint venture, GTSW Bio, with Great Tree Pharmacy.
Joined the Bora Group and secured a stake in Bora Federal.
2022
U.S. red yeast rice products reached 2022 NutraIngredients USA Awards finalist status.
Taiwanese red yeast rice awarded the SNQ National Quality Bronze Award.
Secured the 2022 Taiwan BIO Gold Award for industry excellence in biotechnology.
2021
SunWay is listed on Taiwan Emerging Stock Market
Cooperation with US Florida brand owner
Ranked 9th in the Biotechnology Service Industry in Taiwan’s TOP 5000 Largest Enterprises
2020
Taiwanese product red yeast rice won the Taiwan Health Food Society Nutrition and Health Food Innovation Award.
SunWay is awarded “Taiwan BIO Awards- Emerging Company of the Year“
Cooperation with Belgium distributor
2019
Obtained D & B’s business operation capability certification
Cooperate with NTU Hospital to conduct clinical trials related to probiotics and H. pylori
NTU 101 is honored to be as the cover of Food & Function Journal
Red yeast rice ANKASCIN 568-R was invited to write a review
New red yeast rice raw material 568-P developed
2018
Red Yeast Extract ANKASCIN 568-R Granted New Dietary Ingredient Recognition by the U.S. FDA (#1071)
Accomplished clinical trials on the probiotic Vigiis 101-LAB ingredient’s (gut transition effects)
2017
Acquired 2nd health claim certificate for new red yeast capsules in Taiwan
A food supplement containing ANKASCIN® 568-R was approved by Italian authorities
Clinical results on red yeast ingredient’s blood pressure effects were accepted by a peer-reviewed journal
SunWay’s management system has been certified by TÜV Rheinland
Established Songshan Lake SunWay Biotechnology in Dongguan, Guangdong
Initial public offering
2016
Acquired health claim certificate for new red yeast capsules in Taiwan
Clinical results on red yeast ingredient’s blood sugar effects were accepted by a peer-reviewed journal
Accomplished clinical trial on the probiotic Vigiis 101-LAB ingredient (gut microbiota effects)
2015
The red yeast extract (ANKASCIN 568-R) was accepted by the US FDA as an NDI (New Dietary Ingredient)
Two clinical trials were completed in Taiwan, demonstrating ANKASCIN 568 Plus+ was effective in lowering blood glucose and blood lipids (total cholesterol and low-density lipoprotein cholesterol)
Red yeast and Lactobacillus ingredient supply and contract manufacturing of private label finished products.
2014
Development of Lactobacillus soft sweets.
2013
A red yeast product (ANKASCIN 568) was granted the Health Food Permit (No. A00231).
2012
The main facility was expanded and certified with ISO 22000 and HACCP.
Application and development of non-active Lactobacillus, collagen powder, and herbal tablets.
2011
The fermented manufacturing processes of red yeast-related products were granted patents and certificates from multiple nations.
2010
Probiotic products were awarded the Certification of Symbol of National Quality (SNQ).
Red yeast capsulate products were granted the Certification of Halal and the US federal trademark “HCW”.
2008 - 2009
Developing red yeast products in capsule
The research and technology of Monascus purpureus NTU 568 (red yeast) and Lactobacillus paracasei subsp. paracasei NTU 101 (probiotics) were exclusively authorized by National Taiwan University.
Red yeast (Monascus purpureus) beverages were awarded the Certification of Symbol of National Quality (SNQ).
2007
SunWay Biotech Co., LTD. was established and its facility was qualified for GMP certification.
